Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
NET REVENUE
Clinical testing revenue	$ 55,739	$ 24,875	$ 166,674	$ 71,770
Pharma Services & research revenue	5,022	251	16,919	753
Total Revenue, net	60,761	25,126	183,593	72,523
COST OF REVENUE	33,416	13,955	100,471	40,995
GROSS MARGIN	27,345	11,171	83,122	31,528
Operating expenses:
General and administrative	19,025	7,438	55,810	21,036
Research and development	967	871	3,719	2,342
Sales and marketing	5,958	2,748	18,084	8,569
Total Operating Expenses	25,950	11,057	77,613	31,947
INCOME (LOSS) FROM OPERATIONS	1,395	114	5,509	(419)
Interest expense, net	1,468	239	4,509	623
Income (loss) before taxes	(73)	(125)	1,000	(1,042)
Income tax expense (benefit)	(6)		500	20
NET INCOME (LOSS)	(67)	(125)	500	(1,062)
Deemed dividends on preferred stock	1,840		5,520
Amortization of preferred stock beneficial conversion feature	3,727		11,180
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (5,634)	$ (125)	$ (16,200)	$ (1,062)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.07)	$ 0.00	$ (0.21)	$ (0.02)
Diluted	$ (0.07)	$ 0.00	$ (0.21)	$ (0.02)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	78,145	60,537	77,224	60,414
Diluted	78,145	60,537	77,224	60,414